» Go to news main

Participants needed for various studies

Posted by Pediatrics/Canadian Centre for Vaccinology on January 21, 2020 in General Announcements

The purpose of this study is to measure the level of protection against measles, mumps and varicella (chickenpox) in infants.

Your child is currently protected from these diseases by antibodies (proteins from your immune system) that you transferred to them in pregnancy. These levels of protection decrease quickly in the first year of life, potentially leaving infants at risk of getting these diseases prior to receiving their own immunizations (which in Nova Scotia are given at 12 months of age).

This study will help us determine the level of protection against these diseases in infants of different ages, and to understand whether and for how long infants may be at risk of measles, mumps or chickenpox prior to receiving their own immunizations. The results may help decision-makers ensure that we are protecting infants as best as we can by determining when they should be immunized, and what the risks of developing the measles, mumps and varicella if they are exposed to these diseases.

Your child can take part in this study if:

He/she is 12 months of age or younger.
He/she was born at equal to or greater than 37 weeks gestation.
He/she has no previous history of measles, mumps or varicella infection.
He/she has no underlying health problems that would affect their immune system.

For more information, visit our website here:

Contact information: Jill Mutch

Influenza or ‘flu’ is a highly contagious infection that is caused by a virus (germ) and spread by nasal droplets. Symptoms include sudden
high fever, headache, chills, muscle ache and cough. The flu can also lead to other serious diseases such as pneumonia (an infection of the lungs), which can be dangerous in young children. The flu virus changes a little bit each year so a new vaccine is required each fall to protect against new “strains” year.

Vaccination with a flu vaccine is the best way to prevent influenza and avoid complications and is recommended by public health. Children
under two years of age may not have strong immune responses to regular flu vaccines.

The purpose of this study is to determine if giving the adjuvanted vaccine to children who have not had a flu vaccine before will improve their immune responses to annual flu vaccines.

For more information, visit our website here:

Contact information: Cathy Brown

RSV is a cold-like virus (germ). It infects the airways and lungs. A person with a mild RSV illness may have a cold or a sore throat. A person with severe illness may have problems breathing.

By the age of 2 years almost all children have had an RSV illness. RSV illness is one of the most common reasons why young babies are admitted to the hospital. In severe cases, babies may die from RSV illness. RSV infection can be more serious in young babies, whose airways are still very small and whose immune system cannot fight germs very well. RSV is the most common cause of bronchiolitis (infection of the breathing tubes) and some pneumonia (lung infection) in young babies.

Purpose of the study:

This is the first study of this RSV vaccine in pregnant women. We have already studied this vaccine in healthy women who are not pregnant.
So far, we know that the vaccine can boost antibodies in these non-pregnant women.

The study will test a smaller dose and a larger dose of the vaccine. Each of these doses has been given safely to about 125 women who are
not pregnant.

We are looking for healthy pregnant women aged 18-40 years old to take part in this clinical research study. For more information, visit
our website here:

Contact information: Pamela MacIntyre